In vitro antifungal activity of DNA topoisomerase inhibitors

Medical Mycology

Volumn 50, Issue 3, 2012, Pages 333-336

  Steverding, Dietmar ^a   Evans, Penelope ^a   Msika, Leon ^a   Riley, Benjamin ^a   Wallington, Jerome ^a   Schelenz, Silke ^a,b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Antifungal activities; Aspergillus; Candida; Cryptococcus; DNA topoisomerase inhibitors

Indexed keywords

ACLARUBICIN; AMPHOTERICIN B; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; IRINOTECAN; MITOXANTRONE; TOPOTECAN;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; CANDIDA GLABRATA; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; FUNGUS GROWTH; GROWTH INHIBITION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA GLABRATA; CRYPTOCOCCUS NEOFORMANS; HUMANS; MICROBIAL SENSITIVITY TESTS; TOPOISOMERASE INHIBITORS;

ASPERGILLUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; CANDIDA; CANDIDA GLABRATA; FILOBASIDIELLA NEOFORMANS;

EID: 84858378972     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2011.609186     Document Type: Article

References (24)

1. Castón-Osorio JJ, Rivero A, Torre-Cisneros J. Epidemiology of invasive fungal infection. Int J Antimicrob Agents 2008; 32 (Suppl. 2): S103-109.
2. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-1151. (Pubitemid 37222342)
3. Fostel JM, Montgomery DA, Shen LL. Characterization of DNA topoisomerase I from Candida albicans as a target for drug discovery. Antimicrob Agents Chemother 1992; 36: 2131-2138.
4. Shen LL, Baranowski J, Fostel J, Montgomery DA, Lartey PA. DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs. Antimicrob Agents Chemother 1992; 36: 2778-2784.
5. Taylor A, Giles K, Sarthy AV, McGonigal T, Fostel J. identification of the gene encoding DNA topoisomerase I from Candida albicans. FEMS Microbiol Lett 1996; 138: 113-121. (Pubitemid 26184504)
6. Jiang W, Gerhold D, Kmiec EB, et al. The topoisomerase I gene from Candida albicans. Microbiology 1997; 143: 377-386. (Pubitemid 27092173)
7. Keller BA, Patel S, Fisher LM. Molecular cloning and expression of the Candida albicans TOP2 gene allows study of fungal DNA topoisomerase II inhibitors in yeast. Biochem J 1997; 324: 329-339. (Pubitemid 27229400)
8. Van Dross RT, Rao KV, Eisenberg E, Sanders MM. Cloning and characterization of the Aspergillus nidulans DNA topoisomerase I gene. Gene 1997; 203: 169-174. (Pubitemid 27522127)
9. Del Poeta M, Toffaletti DL, Rude TH, et al. Topoisomerase I is essential in Cryptococcus neoformans: role in pathobiology and as an antifungal target. Genetics 1999; 152: 167-178.
10. Kim KH, Akashi T, Mizuguchi I, Kikuchi A. Cloning and characterization of the gene encoding Aspergillus nidulans DNA topoisomerase II. Gene 1999; 236: 293-301. (Pubitemid 29371794)
11. Corbett KD, Berger JM. Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu Rev Biophys Biomol Struct 2004; 33: 95-118. (Pubitemid 38829953)
12. Kwok SC, Schelenz S, Wang X, Steverding D. In vitro effect of DNA topoisomerase inhibitors on Candida albicans. Med Mycol 2010; 48: 155-160.
13. 50 in studies of drug resistance of malaria parasites. Acta Trop 1993; 55: 257-261.
14. Davey KG, Szekely A, Johnson EM, Warnock DW. Comparison of a new commercial colorimetris microdilution method with a standard method for in vitro susceptibility testing of Candida spp. and Cryptococcus neoformans. J Antimicrob Chemother 1998; 42: 439-444. (Pubitemid 28473002)
15. Yamaguchi H, Uchida K, Nagino K, Matsunaga T. Usefulness of a colorimetric method for testing antifungal drug susceptibility of Aspergillus species to voriconazole. J Infect Chemother 2002; 8: 374-377. (Pubitemid 36077337)
16. Fromting RA, Shadomy HJ, Jacobson ES. Decreased virulence in stable, acapsular mutants of Cryptococcus neoformans. Mycopathologia 1982; 79: 23-29. (Pubitemid 13227139)
17. Peiris V, Oppenheim BA. Antimicrobial activity of cytotoxic drugs may influence isolation of bacteria and fungi from blood cultures. J Clin Pathol 1993; 46: 1124-1125.
18. Kinnunen U, SyrjäläH, Koistinen P, Koskela M. Idarubicin inhibits the growth of bacteria and yeasts in an automated blood culture system. Eur J Clin Microbiol Infect Dis 2009; 28: 301-303.
19. Borchmann P, Hübel K, Schnell R, Engert A. Idarubicin: a brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther 1997; 35: 80-83. (Pubitemid 27081326)
20. Patel K, Craig SB, McBride MG, Palepu NR. Microbial inhibitory properties and stability of topotecan hydrochloride infection. Am J Health Syst Pharm 1998; 55: 1585-1587.
21. Gilles HC, Herriott D, Liang R, et al. Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. Br J Clin Pharmacol 1987; 23: 303-310. (Pubitemid 17108191)
22. Dos Santos N, Waterhouse D, Masin D, et al. Substantial increase in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. J Control Release 2005; 105: 89-105. (Pubitemid 40805478)
23. Gubernator J, Chwastek G, KoryciPka M, et al. The encapsulation of idarubicin within liposomes using the novel EDTA ion gradient method ensures improved drug retention in vitro and in vivo. J Control Release 2010; 146: 68-75.
24. Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 1992; 52: 891-896.